Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological ...

Serum Institute of India Pvt. is gearing up to meet the growing demand for life-saving vaccines, with expectations to double sales in the n...

Japanese drug giant Takeda has partnered with Indian vaccine maker Biological E (BE) to manufacture its Dengue vaccine. BE will increase it...

More than a million children have missed crucial immunizations and hospital births have shown a sharp decline, indicating many women may ha...

Lockdown should not be extreme once economic activity resumes, says the Biocon Managing Director.

As the world focuses on the pandemic, experts fear losing ground in the long fight against other infectious diseases like AIDS, tuberculosi...

"From an epidemiologic standpoint, I don't know if three weeks will be enough. It may require more time," said Venkayya, who was responsibl...

Asian countries spend an estimated $6.5 billion annually in both direct and indirect medical costs due to dengue.

As per the Human Development Reports (HDRs) published annually by the UNDP since 1991, India has consistently improved on the human develop...